Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization

Conditions

Coronary Heart Disease

Keywords

Coronary Revascularization, Sirolimus-eluting stents, Paclitaxel-eluting stents

Brief summary

Context: Sirolimus-eluting stents and paclitaxel-eluting stents, as compared with bare-metal stents, reduce the risk of restenosis. It is unclear whether there are differences in safety and efficacy between the two types of drug-eluting stents. Objective: To determine differences in safety and efficacy between sirolimus and paclitaxel eluting stents.

Detailed description

Design: Randomized controlled, observer-blind trial comparing sirolimus-eluting stents with paclitaxel-eluting stents Patients: 1012 patients undergoing percutaneous coronary intervention. The two groups had similar baseline clinical and angiographic characteristics.

Kyohei Yamaji, Lorenz Räber, Thomas Zanchin, Ernest Spitzer, Christian Zanchin et al. (15 authors)

European Heart Journal2016-08-3094 citations

10.1093/eurheartj/ehw343

Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity

Konstantinos C. Koskinas, George C.M. Siontis, Raffaele Piccolo, Anna Franzone, Alan G. Haynes et al. (13 authors)

Circulation Cardiovascular Interventions2016-01-29116 citations

10.1161/circinterventions.115.003255

Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary intervention

Pascal Vranckx, Bindu Kalesan, Giulio Stefanini, Vasim Farooq, Yoshinobu Onuma et al. (10 authors)

EuroIntervention2015-06-0110 citations

10.4244/eijv11i2a31

Impact of sex on clinical and angiographic outcomes among patients undergoing revascularization with drug-eluting stents.

Stefanini GG, Kalesan B, Pilgrim T, Räber L, Onuma Y, Silber S, Serruys PW, Meier B, Jüni P, Windecker S.

2012-03-0149 citations

10.1016/j.jcin.2011.11.011

SYNTAX score and Clinical SYNTAX score as predictors of very long-term clinical outcomes in patients undergoing percutaneous coronary interventions: a substudy of SIRolimus-eluting stent compared with pacliTAXel-eluting stent for coronary revascularization (SIRTAX) trial.

Girasis C, Garg S, Räber L, Sarno G, Morel MA, Garcia-Garcia HM, Lüscher TF, Serruys PW, Windecker S.

2011-09-27107 citations

10.1093/eurheartj/ehr369

Impact of stent overlap on angiographic and long-term clinical outcome in patients undergoing drug-eluting stent implantation.

Räber L, Jüni P, Löffel L, Wandel S, Cook S, Wenaweser P, Togni M, Vogel R, Seiler C, Eberli F, Lüscher T, Meier B, Windecker S.

2010-03-01112 citations

10.1016/j.jacc.2009.11.052

Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial.

Togni M, Eber S, Widmer J, Billinger M, Wenaweser P, Cook S, Vogel R, Seiler C, Eberli FR, Maier W, Corti R, Roffi M, Lüscher TF, Garachemani A, Hess OM, Wandel S, Meier B, Jüni P, Windecker S.

2007-09-0454 citations

10.1016/j.jacc.2007.06.015

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Interventions

DEVICESirolimus-eluting stent

DEVICEPaclitaxel-eluting stent

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

Patients with either stable angina or an acute coronary syndrome were eligible to participate if they had at least one lesion with stenosis of at least 50 percent in a vessel with a reference diameter between 2.25 and 4.00 mm that was suitable for stent implantation.

Exclusion criteria

Allergy to antiplatelet drugs, heparin, stainless steel, contrast agents, sirolimus, or paclitaxel; participation in another coronary-device study; and terminal illness.

Design outcomes

Primary

Measure	Time frame
Major adverse cardiac events at nine months (composite of cardiac death, myocardial infarction or ischemia-driven target lesion revascularization)	—

Secondary

Measure	Time frame
Clinical: Ischemia-driven target lesion revascularization, target-vessel revascularization, and target-vessel failure (composite of cardiac death, myocardial infarction or ischemia-driven target-vessel revascularization)	—
Angiographic: In-segment late luminal loss	—

Countries

Switzerland

Outcome results

None listed